NGM Biopharmaceuticals, Inc. Analysis
| Analyst Ratings |
|
Average Target Price
|
5.83
|
|
Average Rating
|
3.83
|
|
# Strong Buys
|
2
|
|
# Buys
|
1
|
|
# Holds
|
3
|
|
# Sells
|
0
|
|
# Strong Sells
|
0
|
| Quarterly Earnings History |
| Quarter |
EPS Estimate |
EPS Actual |
EPS Difference |
Surprise Percent |
|
2022-09-30
|
-0.59
|
-0.59
|
0.00
|
0.00%
|
|
2022-06-30
|
-0.55
|
-0.59
|
-0.04
|
-7.27%
|
|
2022-03-31
|
-0.46
|
-0.42
|
0.04
|
8.70%
|
|
2021-12-31
|
-0.36
|
-0.35
|
0.01
|
2.78%
|
|
2021-09-30
|
-0.35
|
-0.37
|
-0.02
|
-5.71%
|
|
2021-06-30
|
-0.37
|
-0.48
|
-0.11
|
-29.73%
|
|
2021-03-31
|
-0.42
|
-0.36
|
0.06
|
14.29%
|
|
2020-12-31
|
-0.47
|
-0.40
|
0.07
|
14.89%
|
| Annual Earnings History |
| Fiscal Year End |
EPS |
|
2022-12-31
|
-1.60
|
|
2021-12-31
|
-1.56
|
|
2020-12-31
|
-1.49
|
|
2019-12-31
|
-1.75
|
|
2018-12-31
|
-0.23
|